With Overactive Bladder, Drug Companies Helped Create $3 Billion Market

MedPage Today, Milwaukee Journal Sentinel, October 15, 2016. Diana Zuckerman, president of the National Center for Health Research noted there is another factor arguing against the use of drugs to treat overactive bladder. “All of these drugs have the potential for serious risk,” she said. “So what’s the actual benefit? To weigh that against risks that can be serious, it’s pretty unimpressive.”

Read More »

Anthem Says Will Not Cover Sarepta’s Approved Duchenne Drug

Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.

Read More »